MetLife Investment Management LLC Decreases Stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

MetLife Investment Management LLC reduced its position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 57.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,287 shares of the company’s stock after selling 49,175 shares during the period. MetLife Investment Management LLC’s holdings in Lyell Immunopharma were worth $50,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Intech Investment Management LLC purchased a new stake in Lyell Immunopharma during the third quarter valued at approximately $52,000. Dimensional Fund Advisors LP raised its position in Lyell Immunopharma by 197.8% during the second quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company’s stock valued at $58,000 after purchasing an additional 26,635 shares during the period. China Universal Asset Management Co. Ltd. raised its position in Lyell Immunopharma by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 49,238 shares of the company’s stock valued at $68,000 after purchasing an additional 19,287 shares during the period. SG Americas Securities LLC raised its position in Lyell Immunopharma by 78.1% during the third quarter. SG Americas Securities LLC now owns 57,566 shares of the company’s stock valued at $79,000 after purchasing an additional 25,247 shares during the period. Finally, Susquehanna Fundamental Investments LLC raised its position in Lyell Immunopharma by 49.5% during the second quarter. Susquehanna Fundamental Investments LLC now owns 128,203 shares of the company’s stock valued at $186,000 after purchasing an additional 42,452 shares during the period. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Lyell Immunopharma Stock Performance

Shares of NASDAQ LYEL opened at $0.92 on Wednesday. The business’s 50 day moving average price is $1.08 and its 200-day moving average price is $1.48. Lyell Immunopharma, Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $3.26. The company has a market cap of $267.39 million, a price-to-earnings ratio of -1.16 and a beta of -0.45.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.03. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The firm had revenue of $0.03 million for the quarter. Sell-side analysts predict that Lyell Immunopharma, Inc. will post -0.8 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on LYEL shares. HC Wainwright restated a “neutral” rating and set a $1.00 price objective on shares of Lyell Immunopharma in a research report on Tuesday, November 12th. Bank of America downgraded Lyell Immunopharma from a “buy” rating to an “underperform” rating and decreased their price objective for the company from $6.00 to $1.00 in a research report on Wednesday, October 30th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.